Geneva, July 14 -- International Clinical Trials Registry received information related to the study (ACTRN12625000707460) titled 'Study of Kite-363 in participants with difficult to treat autoimmune diseases, evaluating efficacy and safety' on July 3.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Masking: Open (masking not used)
Assignment: Other
Type of endpoint: Safety/efficacy
Primary Sponsor: Kite, A Gilead Company
Condition:
Systemic Lupus Erythematosus, with or without lupus nephritis
Systemic Sclerosis
Idiopathic Inflammatory Myopathy
Systemic Lupus Erythematosus, with or without lupus nephritis
Systemic Sclerosis
Idiopathic Inflammatory Myopathy
Inflammatory and Immune System...